Prof. Dr. Lingyu Li | Paraganglioma | Best Researcher Award

The First Hospital of Jilin University | China

Author Profile

Scopus

🌟 LI LINGYU: A LEADER IN TUMOR IMMUNOLOGY AND TRANSLATIONAL MEDICINE

🎓 EARLY ACADEMIC PURSUITS

Born on September 30, 1987, Dr. Li Lingyu demonstrated an early passion for the biomedical sciences. She pursued rigorous academic training in medicine, eventually earning her Doctor of Medicine degree. Her early exposure to clinical oncology and translational research inspired her to delve into tumor biology, neuroendocrine tumors, and immunotherapy—fields in which she would later emerge as a national expert.

👩‍⚕️ PROFESSIONAL ENDEAVORS

Currently serving as Deputy Chief Physician and Associate Professor at the Cancer Center, The First Hospital of Jilin University, Dr. Li Lingyu stands at the forefront of cancer treatment and translational research in China.

Her professional footprint extends well beyond clinical care. She holds pivotal roles across several major academic and volunteer organizations:

  • Deputy Chairperson, New Seedling Committee, Tumor Nutrition Branch, Chinese Anti-Cancer Association (CACS)

  • Member, Specialized Committee for Neuroendocrine Tumors, CACS

  • Young Member, Tumor Markers Committee, CACS

  • Member, Jilin Youth Federation

  • Secretary-General, Youth Volunteer Committee, Jilin Bethune Volunteer Association

She is also a prominent voice in academic publishing:

  • Invited Reviewer, Chinese Medical Journal (English Edition)

  • Editor-in-Chief, Frontiers in Cell and Developmental Biology

  • Editor-in-Chief, Frontiers in Oncology

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PARAGANGLIOMA

Dr. Li Lingyu has built a research portfolio that focuses on the molecular and immunological mechanisms of small cell lung cancer (SCLC), glioblastoma, and tumor immune microenvironments. Her projects are strategically aimed at unraveling resistance to NK cell therapy and immunotherapy, with a strong emphasis on:

  • Endoplasmic reticulum homeostasis

  • Mitochondrial-ER calcium signaling

  • Circular RNAs and encoded peptides

  • Tumor immune evasion mechanisms

She is the Principal Investigator of multiple high-impact grants, notably:

  1. National Natural Science Foundation of China (2025–2028) – $450,000 for work on CD97–SERCA2 complexes in SCLC immunotherapy resistance.

  2. Interdisciplinary Youth Innovation Team of Jilin University – CNY 1 million for tumor immunotherapy innovations.

  3. Tumor Immunity Special Zone Project – CNY 3 million for immune tolerance mechanisms in tumor microenvironments.

  4. Multiple NSFC-funded projects on circular RNA, chromosomal rearrangements, and exosome research.

🌍 IMPACT AND INFLUENCE

Dr. Li Lingyu’s work bridges fundamental biology and clinical application. Her findings are influential in:

  • Designing precision therapy protocols

  • Advancing immune cell-based treatments

  • Improving diagnostic strategies through biomarker development

As a recognized leader among young oncologists and translational researchers in China, she also contributes significantly to scientific mentorship and community health awareness.

Her leadership in national and provincial medical associations also reflects her policy-level influence in shaping the direction of cancer research in China.

📚 ACADEMIC CITES

While exact citation metrics are not listed, the volume and caliber of funded projects and her editorial leadership in two leading journals suggest a robust academic citation profile. Her research articles are likely widely cited in the fields of:

  • Tumor immunology

  • Cancer biomarker discovery

  • Small cell lung cancer mechanisms

🧬 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Li Lingyu's legacy is being built on a foundation of scientific innovation, clinical excellence, and academic leadership. As she leads multi-disciplinary teams, mentors future medical scientists, and publishes transformative research, her trajectory suggests she will:

  • Shape the future of immunotherapeutic strategies in oncology

  • Lead cross-disciplinary collaborations on cancer resistance mechanisms

  • Develop next-generation diagnostic and therapeutic platforms

Her continuing roles in policy, publication, and mentorship will ensure that her impact extends well beyond the laboratory and clinic.

🏆 HIGHLIGHTS OF ACHIEVEMENT

  • 🎖️ Deputy Chief Physician, Associate Professor

  • 🧪 Principal Investigator on 10+ major research projects

  • 🏛️ Editorial leadership in two major scientific journals

  • 👩‍🔬 Recognized young academic leader in tumor biology and immunotherapy

  • Influential member of multiple national cancer research associations

📑NOTABLE PUBLICATIONS

"Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas" 

  • Authors: Z., Luo, Zilan , X., Yan, Xu , Y., Liu, Yang , Y., Ren, Yuan , L., Li, Lingyu
  • Journal: Annals of Medicine
  • Year: 2025

"Full text Full text menu is disabled 0 Citations Article • Open access CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker" 

  • Authors: RAB5A F., Guo, Feifei , N., Du, Nawen , X., Wen, Xue , J., Hu, Jifan , J., Cui, Jiuwei
  • Journal: Cellular and Molecular Life Sciences
  • Year: 2024

"Development and validation of a nomogram prognostic model for small cell lung cancer optimized by age and metastatic pattern " 

  • Authors: H., Guo, Hanfei , H., Tuerxun, Halahati , W., Li, Wenqian , L., Li, Lingyu , J., Cui, Jiuwei
  • Journal: Precision Nutrition
  • Year: 2023
Lingyu Li | Paraganglioma | Best Researcher Award